Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Liquidia Corp
(NQ:
LQDA
)
9.720
-0.435 (-4.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Liquidia Corp
< Previous
1
2
3
Next >
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
September 11, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
September 06, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
August 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Liquidia to Present at Upcoming Investor Conferences
August 28, 2024
From
Liquidia Corporation
Via
GlobeNewswire
LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
August 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Liquidia Corporation (LQDA)
August 27, 2024
From
Kirby McInerney LLP
Via
Business Wire
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
August 22, 2024
From
Liquidia Corporation
Via
GlobeNewswire
LQDA Investors Have Opportunity to Join Liquidia Corporation Securities Fraud Investigation with the Schall Law Firm
August 19, 2024
From
The Schall Law Firm
Via
Business Wire
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
August 19, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
August 16, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
July 31, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
June 18, 2024
From
Liquidia Corporation
Via
GlobeNewswire
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
June 03, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
May 29, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
May 10, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
May 07, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
May 07, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
April 01, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
March 13, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
March 06, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
January 30, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
January 25, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Announces Updates to Operations Leadership
January 19, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
January 08, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
January 05, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation Announces $100 Million in New Financings
January 04, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Liquidia Corporation
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.